Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230332 · ClinicalTrials.gov registry record · Phase 2
Alendronate to Prevent Loss of Bronchoprotection in Asthma
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02230332 is a Phase 2 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 78 participants.
The verdict
NCT02230332, a Phase 2 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
Beta-2-agonists are effective in reducing airway narrowing in asthma and protecting against stimuli that produce bronchoconstriction. The combination of long-acting beta agonists (LABA) and inhaled corticosteroids (ICS) has become the most commonly used asthma controller medication class in the United States, but unfortunately, even when LABAs are added to ICS and used regularly, 58-81% of patients with asthma fail to achieve total control. Regular use of beta-agonists, both short and long-acting, reduces the ability of these agents to protect against the airway narrowing that occurs in asthma in response to bronchoconstrictor stimuli. We refer to this reduced effect as loss of bronchoprotection. In this proof of concept trial we aim to determine if alendronate, which diminishes beta-2 adrenergic receptor internalization, can reduce the loss of bronchoprotection that occurs with regular use of LABAs, even when used in combination with ICS.
Interventions
- DRUG Placebo
- DRUG Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02230332
The ClinicalTrials.gov registry entry for NCT02230332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02230332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02230332 about?
NCT02230332 is a clinical study titled "Alendronate to Prevent Loss of Bronchoprotection in Asthma". Beta-2-agonists are effective in reducing airway narrowing in asthma and protecting against stimuli that produce bronchoconstriction. The combination of long-acting beta agonists (LABA) and inhaled corticosteroids (ICS) has become the most commonly used asthma controller medication class in the Unit...
What is the current status of trial NCT02230332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2015-01. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02230332?
The interventions under investigation include: Placebo (DRUG), Alendronate (DRUG).
Who is sponsoring clinical trial NCT02230332?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.